In Brief: FDA Office of Public Affairs
This article was originally published in The Gray Sheet
FDA Office of Public Affairs: Deputy Commissioner for Policy Donald McLearn will leave the agency for a position at the Washington, D.C. public relations firm Fleishman-Hillard. A replacement likely will be named after appointment of the new FDA Commissioner. McLearn has been at FDA since 1980, serving in various capacities such as deputy director of the publications staff in both the Office of Legislation and Information and the Office of Public Affairs...
You may also be interested in...
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.
In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.